INTRODUCTION
Traditional Chinese Medicine (TCM) has been used to treat various diseases for more than 2500 years. Based on TCM theory, we designed a warming and relieving cold phlegm formula (WRCP), composed of Fuzi (Radix Aconiti Lateralis Preparata), Tubeimu (Rhizoma Bolbostemmatis), Shanglu (Radix Phytolaccae), Sanqi (Radix Notoginseng), and Bihu (Gekko Swinhonis). WRCP was shown to have direct anti-cancer effects in vitro and in vivo. In a human breast MDA-MB-231 xenograft model, WRCP could effectively inhibit tumor growth and induce tumor necrosis without changing body weight or organ indexes. 3, 4 Aconitum was previously shown to have antitumor activity. 5 Tubeimu (Rhizoma Bolbostemmatis) has been used to treat breast cancer for more than 270 years in TCM. 6 A recent study indicated that Tubeimu (Rhizoma Bolbostemmatis) could induce apoptosis in the human breast cancer cell line MDA-MB-231. 7 Tubeimoside I and acetylbenzoylaconine, the respective major active ingredients of Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata), also showed antitumor activities in several cancer cell lines. [8] [9] [10] [11] These results suggest possible synergistic effects between Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata). Here, we aimed to explore the effect of Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata) on MDA-MB-231 and SKBR3 breast cancer cells. and Fuzi (Radix Aconiti Lateralis Preparata) (100 g each) were ground into powder and extracted twice with hot distilled water (1000 and 800 mL, respectively) at 100 ℃ for 30 min. The solutions were combined and centrifuged at 2.2 g for 10 min. The resulting supernatant was filtered, concentrated, and dried to obtain residue (Fuzi: 36.01 g and Tubeimu: 34.03 g). The residue was dissolved in phosphate buffered saline at a concentration of 10 mg/mL and stored at -20 ℃ as the stock extract solution.
MATERIALS AND METHODS

Herbs and preparation of aqueous extracts
Cell culture and reagents MDA-MB-231 and SKBR3 breast cancer cell lines were obtained from Tianjin Medical University Cancer Institute and Hospital (Tianjin, China). MDA-MB-231 cells were cultured in Leibovitz's L-15 medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA) in a free gas exchange with atmospheric air. SKBR3 cells were cultured in DMEM medium (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum at 37 ℃ in a humidified 5% CO2 incubator.
Trypan blue exclusion assay MDA-MB-231 cells were seeded at 1×10 4 cells/well in 24-well plates (Corning, NY, USA). Cells were collected 48 h after treatment with Tubeimu (Rhizoma Bolbostemmatis) at 15.6-500 µg/mL, Fuzi (Radix Aconiti Lateralis Preparata) at 15.6-500 µg/mL or the combination of Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata) at the weight ratio of 1∶1, 2∶1, or 1∶2. The trypan blue exclusion assay was used to determine viable and total cell numbers. This method offers quantitative definitions for antagonism, additive effect and synergism in drug combinations and is widely used in drug combination studies. 1, [12] [13] [14] Fa is the fraction affected, where 1 is equivalent to 100% inhibition. Combination index (CI) was calculated using the CI-isobologram method based on data derived from cells treated with single drugs and drug combinations at the indicated weight ratios and plotted versus Fa. A CI value of less than, equal to, or more than 1 indicate synergistic, additive, and antagonistic effects, respectively. CI values were calculated using the equa- 
MTS assay 1×10
3 SKBR3 cells in 100 µL of culture medium were seeded in each well of a 96-well plate. Cells were then divided into tubeimoside I (Bellancom, Beijing, China) groups (3-10 µg/mL), acetylbenzoylaconine (Bellancom) groups (1.5-20 µg/mL), and combination groups at weight ratios of 1∶1, 2∶1, or 1∶2. Tubeimoside I and acetylbenzoylaconine, are the respective major ingredients of Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata) (Figure 1) . At 44 h after drug treatment, 20-µL MTS reagent (Promega, Madison, WI, USA) was pipetted into each well of the 96-well plate. The plate was then incubated at 37 ℃ for 4 h and the optical density (OD) values were recorded at 490 nm.
Flow cytometry analysis
MDA-MB-231 and SKBR3 cells were seeded at 3 × 10 4 -1× 10 5 cells/well in 6-well plates. Cells were collected 48 h after adding Tubeimu (Rhizoma Bolbostemmatis) (62.5 µg/mL) and/or Fuzi (Radix Aconiti Lateralis Preparata) (62.5 µg/mL). As2O3 was used as a positive control. To detect apoptosis in early and later stages, cells were stained with FITC Annexin V and PI (BD Biosciences, Franklin Lakes, NJ, USA), respectively. For cell cycle analysis, cells were fixed with 75% ethanol and stained with PI alone (50 µg/mL). Apoptosis and DNA distribution were analyzed by flow cytometry (BD FACSCalibur, Franklin Lakes, NJ, USA).
Enzyme-linked immunosorbent assay
MDA-MB-231 cells were seeded at 3 × 10 4 cells/well in 12-well plates. After 24 h, the culture medium was replaced with medium containing Tubeimu (Rhizoma Bolbostemmatis) (62.5 µg/mL) and/or Fuzi (Radix Aconiti Lateralis Preparata) (62.5 µg/mL). Cells were then incubated an additional 72 h. The cell monolayers were then lysed with 100 µL of RIPA buffer for 30 min, collected, and centrifuged at 9.0 × g for 5 min at 4 ℃.
The supernatants were collected and the concentration of aquaporin (AQP) 1 was measured using AQP1 enzyme-linked immunosorbent assay kit (Dongge, Beijing, China) according to the manufacturer's instructions. To determine the effect of the active ingredients of Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata) on cell migration, lower chambers were supplemented with tubeimoside I (3-10 µg/ mL) and/or acetylbenzoylaconine (3-10 µg/mL). Cells were then incubated at 37 ℃ for 12 h, at which point cells on the inner surface of the upper chamber were removed. Cells that penetrated through the chamber were fixed, stained with crystal violet (0.1%), and counted using a light microscope (Olympus, Tokyo, Japan). Confocal microscopy SKBR3 cells were serum-starved for 24 h and seeded at 1 × 10 5 cells/well in 6-well plates. Cells were then divided into the Tubeimu (Rhizoma Bolbostemmatis) group at 62.5 µg/mL, Fuzi (Radix Aconiti Lateralis Preparata) group at 62.5 µg/mL, and combination groups of Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata) at 62.5∶62.5 and 62.5∶31.3 µg/ mL. Twelve hours after drug treatment, cells were first incubated with an antibody against E-cadherin (Abcam, Cambridge, UK) at 1∶100 for 16 h at 4 ℃, followed by incubation with a fluorescence-conjugated secondary antibody (1∶5000) at room temperature for 1 h. To determine the localization and configuration of actin filaments, the cells cultured on coverslips were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Cells were incubated with 1% bovine serum albumin and 2-µg/mL phalloidin rhodamine (Enzo Life Sciences, New York, NY, USA) at 4 ℃ overnight, followed by staining with 4′ ,6-diamidino-2-phenylindole (1 µg/mL). Immunostained cells were mounted using antifade mounting medium and examined using a confocal microscope (Leica, Dresden, Germany). The fluorescence of E-cadherin was quantified as integral optical density.
Wound-healing assay
Statistical analysis
Single-factor analysis of variance was used for data analysis. P < 0.05 was considered statistically significant. Statistical calculations were performed by statistical software SPSS 16.0 (SPSS, Chicago, IL, USA). All values are expressed as the mean ± standard deviation ( x ± s).
RESULTS
Effect of the extract on cell proliferation and cell cycle distribution
Our data showed that Tubeimu (Rhizoma Bolbostemmatis) extract at 15.6-500 µg/mL effectively inhibited the proliferation of MDA-MB-231 cells, while Fuzi (Radix Aconiti Lateralis Preparata) extract at 15.6-500 µg/mL had no influence on proliferation. The CIs of the combined treatments of the two extracts at 1∶1 and 2∶1 weight ratios were less than 1 at every Fa level ranging from 0.1 to 0.9, indicating synergic effects. However, the CI of the combined extracts at 1∶2 was more than 1, indicating antagonistic effects. The dose of combined treatment of the two extracts was less than those of either individual extract while reaching the same Fa (Table 1) . Furthermore, after exposure to combined treatment of the two extract concentrations, 62.5∶ 62.5 µg/mL and 62.5∶31.3 µg/mL, the Fa values were 79.72% and 82.23% and the CI values were 0.83 and 0.74, respectively (Figure 2A ). In the MTS assay, tubeimoside Ⅰ at 3-7 µg/mL, acetylbenzoylaconine at 1.5-20 µg/mL, and control had no effects on the proliferation of SKBR3 cells. Tubeimoside Ⅰ at 10 µg/mL effectively inhibited cell proliferation comparedwith the control group (P < 0.05). The inhibitory effects of combined tubeimoside Ⅰ and acetylbenzoylaconine treatment on cell proliferation at 10∶10 µg/mL and 10∶20 µg/mL were superior to that of tubeimoside Ⅰ treatment at 10 µg/mL (P < 0.01, P < 0.05, respectively). Furthermore, the inhibitory effect of combined treatment at 10∶10 µg/mL was greater than that of 10∶20 µg/mL (P < 0.01) ( Figure 2B ). Fuzi (Radix Aconiti Lateralis Preparata) at 62.5 µg/mL did not influence the cell cycle distribution in MDA-MB-231 cells, while Tubeimu (Rhizoma Bolbostemmatis) at 62.5 µg/mL increased the percentage of G1-phase cells, compared with the control group (P < 0.05). The percentage of G1-phase cells in the Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata) combined treatment group at 62.5∶ 62.5 µg/mL was much higher than those in the groups treated with the two extracts alone ( Figure 3 ). An obvious apoptosis peak before G1 in the combined treatment group was observed, which is consistent with that observed in the apoptosis assay ( Figure 5A ).
Effects of both extractions on cell viability
The Fuzi (Radix Aconiti Lateralis Preparata) extraction had no effect on cell survival rate, cell damage, or AQP1 expression in MDA-MB-231 cells. Meanwhile, the MDA-MB-231 cells became tumid, accompanied by abundant cytoplasmic vacuoles in the cytoplasm, 
A ( 7 ) A ( 1 4 MDA-MB-231 cells were collected 48 h after treatment with RB at 15.6-500 µg/mL, RALP at 15.6-500 µg/mL. The trypan blue exclusion assay was used to determine viable and total cell numbers. Fa is the fraction affected, where 1 is equivalent to 100% inhibition. A2: Fa treated with the combination of RB and RALP. The method was same as that of A1. The administration of drugs was combination of RB and RALP at the weight ratio of 1∶1, 2∶1, or 1∶2. A3: CIs plotted versus Fa. CI was calculated using the CI-isobologram method based on data derived from cells treated with single drugs and drug combinations at the indicated weight ratios and plotted versus Fa. B: Effects of tubeimoside I (T) and acetylbenzoylaconine (A) on SKBR3 cells. B1: SKBR3 cells were seeded and were treated with drugs of T at 3µg/mL and/or A at 1.5-6 µg/mL for 48 h respectively. MTS reagent was used to detect optical density at 490 nm. B2-B4: the method was same as that of B1. B2: the administration of drugs was T at 5µg/mL and/or A at 2.5-10 µg/mL. B3: the administration of drugs was T at 7 µg/mL and/or A at 3.5-14 µg/mL. B4: the administration of drugs was T at 10µg/mL and/or A at 5-20 µg/mL. Compared with the control group, 
Effects of the two extracts on apoptosis
Although the Fuzi (Radix Aconiti Lateralis Preparata) extract at 62.5 and 31.3 µg/mL did not induce apoptosis of MDA-MB-231 cells, Tubeimu (Rhizoma Bolbostemmatis) extract at 62.5 µg/mL effectively induced apoptosis compared with untreated controls and the As2O3 positive control. The apoptotic rate following treatment with both extracts at 62.5∶62.5 µg/mL was much higher than that in the Tubeimu (Rhizoma Bolbostemmatis) extract group, which indicated synergistic induction of apoptosis (P < 0.05). Though the apoptosis rate of SKBR3 cells increased from 3.12 ± 0.69 [Tubeimu (Rhizoma Bolbostemmatis) extract-treated group] to 8.33 ± 1.64 or 5.63 ± 1.76 [Fuzi (Radix Aconiti Lateralis Preparata) group treated with both extracts], no significance was observed ( Figure 5 ). fects on cell migration compared with either tubeimoside I or acetylbenzoylaconine alone. Furthermore, the inhibitory effect on cell migration of combined tubeimoside I and acetylbenzoylaconine in SKBR3 cells was superior to that in MDA-MB-231 cells, which is consistent with the experimental results using aqueous extracts ( Figure 7 ). To determine whether Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata) have effects on epithelial adhesion molecules and the cytoskeleton of SKBR3 cells, we studied the expression of E-cadherin, and localization and configuration of actin filaments. In control cells, actin filaments were distributed in the cytoplasm and accumulated at ruffled cell membranes, accompanied by decreased E-cadherin expression levels. Cells treated with Fuzi (Radix Aconiti Lateralis Preparata) displayed pseudopodia formation in which actin filaments preferentially accumulated at the leading edge of ruffled cell membranes to form lamellipodia and the expression of E-cadherin was less than that in control cells. However, cells treated with Tubeimu (Rhizoma Bolbostemmatis) showed polymerization and reorganization of actin filaments along the cell membrane and in the cytoplasm, accompanied by an increased expression of E-cadherin (P < 0.01). After combined treatment with Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata) at concentrations of 62.5∶62.5 µg/mL and 62.5∶31.3 µg/mL, cells changed into a polygonal shape and displayed decreased membrane ruffles. Actin filaments were mainly localized in the cytoplasm and an additional increase in E-cadherin expression level was observed (P < 0.001) (Figure 8 ).
Effects of the two extracts on cell migration
DISCUSSION
TCM has advocated combinatory therapeutic strategies for more than 2500 years. Guided by the theories of TCM, formulae are designed with a combination of different plants or minerals to increase therapeutic efficacy and decrease adverse effects. Examples include Realgar-Indigo naturalis formula and PHY906, whose efficacies in treating cancer have been established. designed, has demonstrated direct anti-cancer effects on both hepatoma cells in vitro and breast cancer cells in vivo. 3, 4 In this study, we used Fuzi (Radix Aconiti Lateralis Preparata) and Tubeimu (Rhizoma Bolbostemmatis) to investigate the synergistic effects of herbs and the rationale of the formula on breast cancer cells. The median effect principle can quantitatively define antagonism, additive effects, and synergism in drug . C: SKBR3 cells. after serum-starved for 24 h SKBR3 cells were treated with T at 3 µg/mL, and/ or A at 3 or 1.5 µg/mL for 12 h. Cells that penetrated through the chamber were fixed, stained with crystal violet (0.1%), and counted using a light microscope. D-E: The method was same as that of C. D: The administration of drugs was T at 5 µg/mL and/ or A at 5 or 2.5 µg/mL. E: The administration of drugs was A at 10 µg/mL, T at 10 µg/mL, T: A at 10∶10 µg/mL or 10∶5 µg/mL respectively. F-I: MDA-MB-231 cells. The method was same as that of A. F: The administration of drugs was T at 3 µg/mL and/or A at 3 or 1.5 µg/mL. G: The administration of drugs was T at 5 µg/mL and/or A at 5 or 2.5 µg/mL. H: The administration of drugs was T at 7 µg/mL and/or A at 7 or 3.5 µg/mL. I: The administration of drugs was T at 10 µg/mL and/or A at 10 or 5 µg/mL. Compared with the control group, 5 cells/well SKBR3 cells were seeded and divided into the drug treatment groups as follows. A1-1: control group; A1-2: 62.5 µg/mL RALP group, A1-3: 62.5 µg/mL RB group, A1-4: RALP:RB group (62.5∶62.5 µg/mL); A1-5: RALP: RB group (62.5∶31.3 µg/mL). After twelve hours, cells were incubated with antibody against E-cadherin(1∶100) for 16 h at 4 ℃, followed by fluorescence-conjugated secondary antibody (1∶5000) at room temperature for 1 h and then examined using a confocal microscope (×400). A2: The statistical results of the fluorescence of E-cadherin as integral optical density. Compared with the control group, a P < 0.01; compared with the RALP (62.5) group, b P < 0.001; compared with the RB (62.5) group, c P < 0.001; compared with the RALP∶RB. B. actin filaments SKBR3 cells cells cultured on coverslips were treated with different drugs as follows. B1: control group; B2: 62.5 µg/mL RALP group, B3: 31.3 µg/mL RALP group; B4: 62.5 µg/mL RB group; B5: RALP∶RB group (62.5∶ 62.5 µg/mL); B6: RALP∶RB group (62.5∶31.3 µg/mL). Twelve hours later, cells were incubated with 2-µg/mL phalloidin rhodamine at 4℃ overnight, followed by staining with 4′,6-diamidino-2-phenylindole (1 µg/mL) and examined using a confocal microscope (× 600). RB: Tubeimu (Rhizoma Bolbostemmatis); RALP: Fuzi (Radix Aconiti Lateralis Praeparata). inhibitory effect on cell migration was not because of the cytotoxicity or proliferation inhibition effect of drugs. Cell adhesion and migration are interdependent cellular processes whose alterations lead to the acquisition of a more motile phenotype by cancer cells, allowing for tumor migration. Decreased expression of the epithelial adhesion molecule E-cadherin plays a key role in the acquisition of the invasive phenotype of many tumors. The cytoskeleton provides the basic infrastructure for the maintenance of cell motility. 15 Tumor cell migration depends mainly on the polymerization and reorganization of actin filaments. The formation of distinct actin-based membrane protrusions at the cell front, such as lamellipodia, is at the core of this process. 16 By generating both pushing and contractile forces, actin filaments are capable of promoting cell motility.
17
SKBR3 cells treated with Fuzi (Radix Aconiti Lateralis Preparata) presented a decreased expression of E-cadherin and accumulated actin filaments at the leading edge of ruffled cell membranes to form protrusions relative to control cells. However, SKBR3 cells treated with Tubeimu (Rhizoma Bolbostemmatis) in combination with Fuzi (Radix Aconiti Lateralis Preparata) showed an increased expression of E-cadherin and reorganization of actin filaments in the cytoplasm along with decreased formation of membrane ruffles relative to cells treated with Tubeimu (Rhizoma Bolbostemmatis) alone. Aquaporins are one type of membrane protein that regulate water transport across the cell membrane. The elevated expression of aquaporin-1 (AQP1) assists water uptake and can result in a cell swelling phenotype. 18, 19 Tubeimoside 1, a triterpenoid saponin extracted from Tubeimu (Rhizoma Bolbostemmatis), is cytotoxic in several human cancer cell lines. 11, [20] [21] [22] [23] However, in trypan blue exclusion assay, combined treatment with Fuzi (Radix Aconiti Lateralis Preparata) and Tubeimu (Rhizoma Bolbostemmatis) did not increase cytotoxicity when compared with Tubeimu (Rhizoma Bolbostemmatis) alone, which is partly because there were no changes in the expression of AQP1. The apoptotic percentage of MDA-MB-231 cells treated with Fuzi (Radix Aconiti Lateralis Preparata) and Tubeimu (Rhizoma Bolbostemmatis) was also much higher than those from Fuzi (Radix Aconiti Lateralis Preparata) or Tubeimu (Rhizoma Bolbostemmatis) alone. Because the apoptotic bodies were free from trypan blue dyeing, the synergistic effect on inducing cell apoptosis was observed but no difference in viability was observed. Acetylbenzoylaconine and tubeimoside Ⅰ, the major active ingredients of Tubeimu (Rhizoma Bolbostemmatis) and Fuzi (Radix Aconiti Lateralis Preparata), were previously shown to inhibit proliferation and induce apoptosis in several cancer cell lines. [8] [9] [10] [11] Our results show that acetylbenzoylaconine plus tubeimoside Ⅰ exhibited a synergistic inhibitory effect on cell proliferation and migration, which was consistent with the results of the aqueous extracts. However, the promotion effect on cell migration of acetylbenzoylaconine was not observed, which is because not all active ingredients from Fuzi (Radix Aconiti Lateralis Preparata) were tested, such as mesaconitine and hypaconitine. In conclusion, our findings demonstrate that the inhibitory effects of Tubeimu (Rhizoma Bolbostemmatis) on the proliferation and migration of cell line MDA-MB-231 and SKBR3 are enhanced when used with Fuzi (Radix Aconiti Lateralis Preparata) extract. Furthermore, the promotion effect of Fuzi (Radix Aconiti Lateralis Preparata) extract on the migration of MDA-MB-231 and SKBR3 cells was reduced when combined with Tubeimu (Rhizoma Bolbostemmatis). We further demonstrated that acetylbenzoylaconine and tubeimoside I acted as the essential components in the extracts of Fuzi (Radix Aconiti Lateralis Preparata) and Tubeimu (Rhizoma Bolbostemmatis), exerting synergistic effects on MDA-MB-231 and SKBR3 cells.
